García-Sáenz, J. A., Marmé, F., Untch, M., Bonnefoi, H., Kim, S., Bear, H., . . . Rugo, H. S. (2024). Patient-reported outcomes in high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study. European journal of cancer, 196, . https://doi.org/10.1016/j.ejca.2023.113420
Chicago-Zitierstil (17. Ausg.)García-Sáenz, José Angel, et al. "Patient-reported Outcomes in High-risk HR+/HER2-early Breast Cancer Patients Treated with Endocrine Therapy with or Without Palbociclib Within the Randomized PENELOPEB Study." European Journal of Cancer 196 (2024). https://doi.org/10.1016/j.ejca.2023.113420.
MLA-Zitierstil (9. Ausg.)García-Sáenz, José Angel, et al. "Patient-reported Outcomes in High-risk HR+/HER2-early Breast Cancer Patients Treated with Endocrine Therapy with or Without Palbociclib Within the Randomized PENELOPEB Study." European Journal of Cancer, vol. 196, 2024, https://doi.org/10.1016/j.ejca.2023.113420.